Lutein, Omega-3 Fatty Acids and Zeaxanthin: study protocols
8 study groups took Lutein together with Omega-3 Fatty Acids and Zeaxanthin. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Lutein
8 study groups in 6 studies say how much Lutein participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg to 10 mg, 88% of 8 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mg to 10 mg | 7 |
| 10 mg to 25 mg | 1 |
Dose per serving from research: Omega-3 Fatty Acids
6 study groups in 5 studies say how much Omega-3 Fatty Acids participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 50% of 6 study groups.
| Daily dose | Study groups |
|---|---|
| 25 mg to 50 mg | 1 |
| 50 mg to 100 mg | 2 |
| 100 mg to 250 mg | 0 |
| 250 mg to 500 mg | 0 |
| 500 mg to 1 g | 3 |
Dose per serving from research: Zeaxanthin
8 study groups in 6 studies say how much Zeaxanthin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg, 75% of 8 study groups.
| Daily dose | Study groups |
|---|---|
| 500 mcg to 1 mg | 2 |
| 1 mg to 2.5 mg | 6 |
Commonly used together
7 of 8 study groups took Lutein, Omega-3 Fatty Acids and Zeaxanthin with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Docosahexaenoic Acid | 5 |
8 study groups
| Study | |||||
|---|---|---|---|---|---|
| Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial 2013 · lutein + zeaxanthin and DHA + EPA group · Adults aged 50 to 85 years at risk for progression to advanced age-related macular degeneration, with bilateral large drusen or large drusen in one eye and advanced AMD in the fellow eye | 10 mg | 650 mg | 2 mg | 5 years | — |
| Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3 2014 · lutein/zeaxanthin and DHA/EPA · Adults with high risk of progression to late age-related macular degeneration; mean age 73.1 years; sex not specified | 10 mg | 1 g | 2 mg | 1789 days | — |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 2 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 10 mg | 100 mg | 2 mg | 12 weeks | 96 |
| Effects of Long-Chain Polyunsaturated Fatty Acids in Combination with Lutein and Zeaxanthin on Episodic Memory in Healthy Older Adults 2023 · LCPUFAs + LZ group, Trial 1 · Healthy Japanese adults aged 55–79 with memory complaints and no dementia; cognitive-decline subgroup had MoCA-J scores below 23 | 10 mg | 100 mg | 2 mg | 24 weeks | 40 |
| Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial 2013 · group 1 · Individuals with nonexudative age-related macular degeneration; age and sex not specified | 10 mg | 30 mg | 1 mg | 1 year | — |
| Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study 2013 · D2 (twice daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified | 20 mg | — | 2 mg | 1 year | 55 |
| Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study 2013 · D1 (once daily) · Patients with non-exudative age-related macular degeneration; age and sex not specified | 10 mg | — | 1 mg | 1 year | 50 |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 lutein/zeaxanthin plus DHA/EPA · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye | 10 mg | 650 mg | 2 mg | 5 years | — |